Assisted dying bill: How both sides of debate reacted to historic vote
People on both sides of the assisted dying debate have told Sky News how they feel about the outcome of today's vote – and while some are popping open champagne, others are "incredibly disappointed".
More than 300 MPs this afternoon backed a bill that gives people in England and Wales who have less than six months to live the right to apply for an assisted death.
Each request will be evaluated by two doctors and a panel featuring a social worker, senior legal figure and psychiatrist.
Today's historic vote means the Terminally Ill Adults (End of Life) Bill will now go to the House of Lords for further scrutiny before becoming law.
Following the landmark vote, individuals for and against it have shared their feelings on the result.
Frank Tate-Sutton - For
6:04
Frank Tate-Sutton is terminally ill and told Sky News she's relieved the bill has passed, even though the law won't be changed in time for her.
"These are happy tears," she said. "I am emotional. It's a very difficult subject for everybody."
Ms Tate-Sutton said her quality of life is "very important - and I'm losing it".
"I don't want to die without dignity, without it being my choice, without my family knowing that this is what I want," she continued.
"As much as they [my family] want me alive, do they want to see me lying in my living room in a hospital bed, taking all these drugs, not being able to talk, not being able to control my bodily functions?
"That is not a life, for me - living on all the medications and not being able to exist without that… the side effects and everything."
Mike Smith - Against
5:20
Mike Smith is a spokesperson for the disability rights group Not Dead Yet - and he has been left "incredibly disappointed" by the outcome of the vote.
"This particular bill had so many failings in the way safeguards are constructed and the significant scope for coercion, whether it's overt or subliminal," he said.
Mr Smith says he fears some people will "end up ending their lives earlier than they should do or want to".
"There are so many disabled people around the country that have told us they're absolutely scared."
"I think it's this inherent fear people have about being disabled that drives this very emotional response on this really complex topic," he explained.
"What we know is, with good palliative care, social care, access to housing and an income, many disabled people ... can lead amazing lives."
6:48
Rebecca Wilcox and her TV presenter mother Dame Esther Rantzen, who has terminal cancer, have long been campaigning for a change to the UK's law on assisted dying.
Speaking from Parliament Square as fellow supporters of the bill popped champagne behind her, Ms Wilcox described today's vote as "an extraordinary moment".
"It means so much to me," she said. "I spoke to mum and her one word to describe it was 'wow'.
"She didn't think she was going to live to see the debate, let alone a conclusion that went our way."
In response to concerns about safeguarding, she said it will "bring in layer upon layer of safeguards".
"We're going to have scrutiny upon scrutiny for every case and at the moment, there is no scrutiny," she said. "Coercion could be happening as we speak.
"There is now protection for vulnerable people, by having this bill passed."
Dr Gordon Macdonald - Against
Dr Macdonald said the bill passing with a majority of 23 - less than half what its second reading achieved - is proof that "the more people have thought about this issue, the more they've had doubts".
The doctor, who is the CEO of anti-euthanasia organisation Care not Killing, said: "We will see what happens when it gets to the [House of] Lords, the Lords will hopefully give it more rigorous scrutiny than happened in the Commons".
His biggest concern is "for people who are vulnerable, who will feel pressure to end their lives".
"That might come from external forces, but it's more likely to just be internalised pressure," Dr Macdonald said.
"They'll feel they're a burden on their family and friends, conscious of the cost of care, and think they should do the decent thing, as they would see it in that thinking."
It's "of course a terrible message for society to send out to people," he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
31 minutes ago
- The Independent
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
Daily Mail
41 minutes ago
- Daily Mail
ANDREW NEIL: No future UK government has a hope of making things better if it can't reform our incompetent Left-wing, WFH civil service
Former Tory Cabinet minister-turned-magazine editor, Michael Gove, this week revealed that, as Education Secretary, he had to overrule civil servants who wanted to suppress newspaper revelations about in Rotherham. The local council requested the government join it in legal action to prevent The Times from publishing details of its ground-breaking investigation into the scandal. Some senior civil servants in his department advised Gove to join in this bid to muzzle the press.
Daily Mail
an hour ago
- Daily Mail
Erectile dysfunction drug Viagra has surprise new health benefit, scientists find - offering new hope to 3million ageing Britons
A surprising new health benefit has emerged from the sex drug Viagra - which means three million ageing Britons can now also enjoy a harder skull. The little blue tablet was found to increase the production of vital bone cells, preventing back pain and fractures in old age. Sildenafil - also known as Viagra - can help human stem cells transform into osteoblasts which help the human skeleton regenerate as it is completely replaced roughly once every 10 years. As humans get older, they lose more bone than is built, increasing the risk of breaks or osteoporosis, which makes bones brittle and painful. Follow-up tests on mice by Peking University also suggested a prevention of bone loss. Dr Menglong Hu and Dr Likun Wu told MailOnline: 'Our findings offer new insights into the physiological effects of the medicine. 'Sildenafil enhanced stem cell osteogenic differentiation and inhibited bone loss — it may usefully treat osteoporosis.' Viagra was invented as a heart drug in the 1980s before being found to help with erectile dysfunction. Some studies suggest it may also help reduce the risk of dementia. However, the have been cautions over the years that the drug could have some negative side effects, in particular if taken too much. A large quantity of the drug could result in a painful, 'uncomfortably and disproportionately large erection' called a priapism which could go on for hours. Some experts also found regularly taking the common drug may raise the risk of three serious eye conditions. Common side effects may include headaches, hot flushes, nausea, indigestion, dizziness and a stuffy nose. Nearly half of men between the ages of 40 and 70 suffer from erectile dysfunction in the UK - this is more than 4.5 million people. Though, reports suggest Viagra is now even becoming increasingly popular with younger individuals in their 20s and 30s. Last year, it emerged Viagra may help prevent dementia by boosting blood flow in the brain. 'This is the first trial to show that sildenafil gets into the blood vessels in the brain in people with this condition, improving blood flow and how responsive these blood vessels are,'Dr Alastair Webb, a neurologist and study author at Oxford University said.
